HGH Fragment 176-191 vs Tirzepatide
Side-by-side comparison of HGH Fragment 176-191 and Tirzepatide: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
HGH Fragment 176-191
Tirzepatide
HGH Fragment 176-191
HGH Fragment 176-191 (also written HGH Frag 176-191, hGH Fragment 176-191, and frequently appearing in clinical literature as AOD-9604 — "Anti-Obesity Drug 9604") is a synthetic peptide corresponding to the C-terminal…
Lowest listed price: $49.99 across 1 listing
Full HGH Fragment 176-191 profileTirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…
Lowest listed price: $49.00 across 14 listings
Full Tirzepatide profileSide-by-side comparison
| Attribute | HGH Fragment 176-191 | Tirzepatide |
|---|---|---|
| Category | Metabolic & Weight Loss | Metabolic & Weight Loss |
| Research Stage | Phase 2 (discontinued) | FDA Approved |
| Mechanism of Action | HGH Fragment 176-191's proposed mechanism of action is grounded in the structural dissection of the native human growth hormone molecule. Full-length hGH (residues 1-191) is a 22 kDa peptide that binds two distinct functional domains to the growth hormone… | Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… |
| Half-Life | ~30 minutes (short plasma half-life) | ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification |
| Typical Dose Range | 250-500 mcg | 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose |
| Dosing Frequency | Once or twice daily, fasted | Once weekly subcutaneous injection |
| Administration | — | Subcutaneous (weekly) |
| Side Effects | HGH Fragment 176-191 / AOD-9604 has been reported as well tolerated in Phase 1 and Phase 2 trials, with side effects that were mostly mild and self-limiting. However, "well tolerated in a Phase 2 trial that failed its primary endpoint" is a different safety… | Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. |
| Molecular Weight | 1815.1 g/mol | 4813.5 Da |
| Common Vial Sizes | — | 5mg, 10mg, 15mg |
Price tracking
Price History
3 data points- BM
- Half Nattys
- Ion Peptide
HGH Fragment 176-191: potential benefits
- Targeted fat loss
- Visceral fat reduction
- No insulin resistance
- Metabolic improvement
- No IGF-1 elevation
Tirzepatide: potential benefits
- Mean body weight reduction of 22.5% at 72 weeks - highest of any anti-obesity medication (PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
Frequently asked
What's the difference between HGH Fragment 176-191 and Tirzepatide?
HGH Fragment 176-191 is a metabolic & weight loss that hgh fragment 176-191's proposed mechanism of action is grounded in the structural dissection of the native human growth hormone molecule. full-length hgh (residues 1-191) is a 22…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (~30 minutes (short plasma half-life) vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, HGH Fragment 176-191 or Tirzepatide?
HGH Fragment 176-191 has a half-life of ~30 minutes (short plasma half-life). Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, HGH Fragment 176-191 or Tirzepatide?
Lowest listed price on BodyHackGuide: HGH Fragment 176-191 from $49.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack HGH Fragment 176-191 and Tirzepatide?
Stacking depends on mechanism overlap, safety profile, and goals. HGH Fragment 176-191 and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy HGH Fragment 176-191 or Tirzepatide
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.